Sitemap - 2024 - The California Stem Cell Report
A Thankful Mother, a UCLA Researcher and Snowboarding: A Telling Story for CIRM
Tracking the Wild CIRM: Sweeping Overviews of the Stem Cell/Gene Therapy Agency Are Upcoming
20th Anniversary of California's $12 Billion Stem Cell Program: Kudos and Criticism
California's Stem Cell Agency Receives a $1 Billion Validation
Bubble Baby Disease Treatment Gets $15 Million More from California Stem Cell Agency
California Adds $147 Million to its Next Six Months Spending for Gene and Stem Cell Research
Is CIRM Pushing Money Out the Door Fast Enough? A Look at the Money Trail
Trump/RFK Jr. and Gene Therapy/Stem Cells: Not a Marriage Made in Heaven
Trump's RFK Jr. Nomination Triggers Condemnation Wave on Internet and Media
Counting CIRM Dollars: Research Awards to Total $147 Million in First Half of Next Year
RFK Jr. Seeking to Stamp Out FDA Regulation of Snake-Oil, Stem-Cell Clinics
Going 'Wild' After the Election: A Look at Alarm and Angst in the Biomedical Research World
CIRM's 'Daring,' $26 Million Bet on a Treatment for a Deadly Muscular Disease
The California Stem Cell Program's Paucity of Critics
California is Building a New Path to Rare Disease Cures; First Target is Neuro Afflictions
From the NY Times: A 12-year-old and His Grueling Genetic Path to be Treated for Sickle Cell Disease
A Show-and-Tell This Week for California's Alpha Clinic Stem Cell Network
California Scientist Jeanne Loring Named as One of 20 Female Biopharma Groundbreakers
Pluses and Minuses: How 17,000 Words Shape a $12 Billion Stem Cell and Gene Therapy Program
The State of Cell and Gene Therapies? Some Indications of Better Times Ahead
Two Recipients of the MacArthur 'Genius' Awards and Their Ties to California's Stem Cell Agency
New Clarifications on Pause for Research Applications at California Stem Cell/Gene Therapy Program
Six Month Pause on Research Applications at California's Stem Cell and Gene Therapy Program
How Does California's Stem Cell and Gene Therapy Agency Define SAF, and Why Is It Important?
California's Stem Cell and Gene Therapy Program Awards Nearly $29 Million Last Week
Correction: Changes in Figures For Two of CIRM's New Goals
California Gene and Stem Cell Agency Sets Major, New Priorities for $3.9 Billion in Research Funding
Text of What CIRM Had to Say About its New Priorities for $3.9 Billion
New Chief Scientific Officer Named at California's $12 Billion Stem Cell and Gene Therapy Agency
California's Gene Therapy Program Not Isolated from Balky Insurance Companies
'All Not Well in Gene Therapy World' -- Denial of Coverage, Delays and Complications
California Research Agency Targeting Multimillion-Dollar Gene Therapy Costs
Update on Ruckus in ReMind: New Details on $12 Million Application involving a Tie Vote
Ruckus in $68 Million, Neuro Disease Round at California Stem Cell/Gene Therapy Agency
Spinal Cord Injury, California Stem Cell Millions and a Patient's Story
Rare Diseases Receive Preliminary Research Boost From California's Gene Therapy/Stem Cell Agency
CIRM's Mystery 'Updates' Challenge its Adherence to Openness and Transparency
Seventeen Apply for California's Millions in Clinical Research; Twelve Will Be Rejected
Next Up in New Priorities for Billions in CIRM Spending: Manufacturing and Disruption?
Can a $4 Million Gene Therapy be 'Affordable?' California Tackles the Question Next Week
In Case You Missed It: Dr. Moustache Scores Again with the Bubble Baby Treatment
Text from UCLA Researcher Donald Kohn on his Bubble Baby Clinical Trial
Dr. Moustache and the Bubble Baby Disease: A CIRM Success Story
Kamala Harris on Hypotheses: A Heritage from Her Cancer Researcher Mom
Trail Guide to $3.9 Billion in Looming Changes at California's Stem Cell and Gene Therapy Program
New CEO at California's Stem Cell Agency Brings 26 Years Investment Banking Experience
CIRM's Priority Review: Rare Disease Research Advocates Hear Assurances
Looking for Work? Want to Help Give Away Billions of Dollars?
New President/CEO for California's $12 Billion Stem Cell and Gene Therapy Program: Jonathan Thomas
California's Stem Cell and Gene Therapy Priorities: New Proposal to Back 'Platform' Technologies
CIRM Caps Off $237 Million in Clinical Stage Funding as It Reexamines Its Priorities
Text of Comments by Mike Graglia to the CIRM Board re Funding of Rare Disease Research
$3.9 Billion Left for California's Stem Cell and Gene Therapy Program; What Will it Finance?
Text of Kim Nye's Statement on Rare Diseases and Changing CIRM Priorities
New CEO for $12 Billion, California Stem Cell Agency Expected on July 9
1,000 Strong: Rare Disease Advocates Pitch for Billions in Research from California Stem Cell Agency
Biopolitical Times on CIRM's 'Depressingly Small Number of Effective Treatments or Cures'
CIRM's Not-So-Simple Multibillion Dollar Finances and How a Direct Democracy Tool Shapes Them
Search for New CEO at $12 Billion Stem Cell/Gene Therapy Program Extends Into July
Quote of the Day: Fauci on Trump
Newest CIRM Board Member is USC Medical School Dean Carolyn Meltzer
CIRM in 'Limbo' and Fighting 'Uphill Battle,' Says San Francisco Business Times
All the News Fit to Print about California's Search for Revolutionary Stem Cell and Gene Therapies
Dysfunction, Bifurcated Management and $12 Billion: A Call for Reevalution of CIRM
From CEO to Financial: Risks in California's Multibillion-Dollar Stem Cell/Genetic Research Program
Tentacles, Railroads and California Stem Cell Finances: Looking for Greater Returns
Google AI and Stem Cells: California Researcher Tests the AI Results, Says They Fail
The CIRM CEO Search: Job Interviews Likely Next Week at the Stem Cell and Gene Therapy Agency
Lifting the Hold on Applications: CIRM Proposes New Screening Plan for Clinical Research Awards
CIRM's Multibillion Dollar Spending Priorities: Affordability and Accessibility on Table Tomorrow
A Look Back and a Look Ahead After a Break at the California Stem Cell Report
The End of the Anti-Cancer, 'Don't Eat Me' Effort at Gilead; Blow to California Stem Cell Agency
Time to Speak Out: Who Will be the Winners and Losers in CIRM's New Priorities?
Dementia Advocate Urges More Funds for Dementia Research from State Stem Cell Agency
$1.1 Billion at Stake in California for Neuro Disease Research at Hearing Next Week
No Revolutionaries Need Apply to Lead California's $12 Billion Stem Cell/Gene Therapy Program
CIRM's 'Adventure with a Deadline:' How Billions will be Spent Pursuing Stem Cell and Gene Therapies
California's Multibillion-Dollar Stem Cell and Gene Therapy Agency Headed Towards New Directions
California Breaks Century Mark in Funding Clinical Trials for Stem Cell and Gene Therapies
Q&A on CIRM's Plans to Suspend Clinical Applications for Five Months
The CIRM CEO Search: New President by June 1, That's the Timetable
Once Terrific News for California Stem Cell Agency Turned Negative Today
Golden State is Great for Stem Cell and Gene Therapy Research, Says BIOCom California Chief Panetta.
San Francisco Lawsuit Charges: A Missing Skull, Alleged Retaliation and CIRM Working Group Member
Human Embryo Models and California Regulation: More Info from CIRM Now Available
Update on Klein-CalPERS Dispute: Klein Says Allegations 'Provably False'
$38 Million Dispute Between California State Retirement Fund and 'Father' of State Stem Cell Agency
From Morocco to San Diego: One-Person Clinical Trials, Gene Therapies and CIRM
California Neuro Disease Research Update: A Search for Unique Opportunities and Bottlenecks to Break
California's Stem Cell Agency Hides Top-Notch Equity and Inclusion Plans From the Public
A Quicky Review of CIRM Finances; More Scrutiny of Stem Cell Agency Promised in February